2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH ANDREA APOLO
Immune Checkpoint Inhibitors Trials in Urothelial Cancer: Recent Updates and Future Outlook

VIEW ALL BLADDER CANCER VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH TOM KEANE
A Look at Established Paradigms in Androgen Deprivation Therapy in the Treatment of Advanced Prostate Cancer

VIEW ALL ADV PROSTATE VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH JEREMIE CALAIS
Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning

VIEW ALL IMAGING VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH FRED SAAD
Delaying Disease Progression in Early Nonmetastatic CRPC Treatment

VIEW ALL nmCRPC VIDEOS

Featured Videos

#AUA14 - Early experience of radium-223 treatment for metastatic castrate resistant prostate cancer: A preliminary report - Session Highlights

ORLANDO, FL USA (UroToday.com) - Radium-223 has recently been introduced for the treatment of metastatic castrate resistant prostate cancer (mCRPC). Compared to its counterparts, Sm153 and Sr89, Ra-223 has a favorable side effect profile given its cytotoxic mechanism of action and excretion. Dr Marc Bienz from the Montreal presented data on short-term pain evolution, morbidity, and hematologic profile of patients with mCRPC treated with Ra-223. In total, 19 mCRPC patients treated with Ra-223 were included for analysis. Injections were administered monthly in accordance with FDA recommendations. Pain patterns were classified by groups into no/minimal pain relief, worsening pain, and pain improvement.

auaFollowing the first and second injections, 21.5% and 44.4% reported reduced pain symptoms, respectively. By the third injection, 50% had pain relief, and 21% reached total pain remission by the third injection. Of note, pain symptoms worsened in 10.5%. Side effects included diarrhea, constipation, nausea, vomiting, bone pain flair response, and lower limb edema in 31.6%, 5.3%, 26.3%, 5.3%, 26.3% and 10.5%, respectively. Dr. Bienz concluded that short-term results demonstrate promising bone-pain relief in half of patients even after only three injections and with mild side effects.

Presented by Marc Bienz at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Montreal, Quebec Canada

Written by Jeffrey J. Tomaszewski, MD, medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 4 Issue 1

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe